0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-3

Siglec-3

Brief Information

Name:Myeloid cell surface antigen CD33
Target Synonym:Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD3-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Siglec-3, His Tag (Cat. No. CD3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD3-HF224-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human Siglec-3, His Tag (Cat. No.CD3-HF224) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD3-H5259-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3, Llama IgG2b Fc Tag, low endotoxin (Cat. No. CD3-H5259) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD3-H5257-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3, Fc Tag (Cat. No. CD3-H5257) with an affinity constant of 0.329 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CD33,SIGLEC3,gp67

Background

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gemtuzumab ozogamicin CDP-771; CMA-676; CL-555201; WAY-CMA-676; hP67.6-calicheamicin Approved Ucb Sa, Pfizer Inc Mylotarg EU Leukemia, Myeloid, Acute Pfizer Europe Ma Eeig 2000-05-17 Leukemia; Leukemia, Myeloid, Acute Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GEM-333 GEM-333 Phase 1 Clinical Gemoab Monoconals Leukemia, Myeloid, Acute Details
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Leukemia, Myeloid, Acute Details
AMV-564 T-564; AMV-564 Phase 1 Clinical Amphivena Therapeutics Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CART-33 (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia, Myeloid, Acute Details
CD123-CD33 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute Details
Anti-CD33 CAR-NK cell therapy (PersonGen Biomedicine) Phase 2 Clinical Leukemia, Myeloid, Acute Details
Anti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology) Phase 1 Clinical Ziopharm Oncology, Intrexon Co Leukemia, Myeloid, Acute Details
ICG-136 ICG-136 Phase 1 Clinical Icell Gene Therapeutics Leukemia, Myeloid, Acute Details
AMG-673 AMG673; AMG-673 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
AL-003 AL-003 Phase 1 Clinical Abbvie Inc, Alector Alzheimer Disease Details
Anti-CD33/CLL-1 CAR-T (Legend) Phase 1 Clinical Leukemia, Promyelocytic, Acute Details
JNJ-67571244 JNJ-67571244; JNJ-67371244; JNJ-1244 Phase 1 Clinical Johnson & Johnson Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
BI-836858 BI-836858 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Phase 2 Clinical University Of Minnesota, Oxis Biotech Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute Details
CD33 CAR T Cells(Beijing Boren Hospital) Phase 1 Clinical Beijing Boren Hospital Neoplasms Details
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR Phase 1 Clinical Icell Gene Therapeutics, Chengdu Military General Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Lintuzumab Ac-225 (Actinium Pharmaceuticals) 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 Phase 2 Clinical Pdl Biopharma Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Leukemia, Myeloid, Acute Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details
AMG-330 MT-114; AMG-330 Phase 1 Clinical Amgen Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Lintuzumab-gelonin conjugate Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop